Holen Sie sich die Stockscreener-App
3.63
5.52%
0.19
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals Earnings Call Shows Efficient Progress - TipRanks
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion (RXRX) Range: Ends Down by 4.86% at $3.33 in Latest Trading; Range Check: the Current Price Sits Inside the Supplied Technical Range for the Current SessionRisk Parity Rebalance - vinanet.vn
Recursion Pharmaceuticals Stock Climbs 13% As AI Drug Pipeline Progress And Spending Cuts Boost Sentiment - TIKR.com
Recursion, Novavax, Crispr Therapeutics Stocks Slip Premarket After Cancer Therapy RallyRecursion Phar - Benzinga
RXRX Stock Steadies As AI Drug Platform Gains Traction And Cash Burn Tightens - StocksToTrade
Recursion Pharmaceuticals Stock (RXRX) Opinions on Clinical Pipeline and AI Platform Developments - Quiver Quantitative
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Hallett David - Moomoo
Recursion (NASDAQ: RXRX) CEO's 80K shares withheld for RSU taxes - Stock Titan
Recursion (NASDAQ: RXRX) CSO sees 26K shares withheld for taxes - Stock Titan
Recursion Pharmaceuticals Inc (RXRX) News, Articles, Events & Latest Updates - Stocktwits
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci - The Globe and Mail
Recursion Pharmaceuticals (RXRX) Slips 1.58% as Stock Holds Above Key $2.95 SupportTriple EMA - vinanet.vn
Recursion Pharmaceuticals (RXRX) Dips 1.42% to $3.12 as Key Support Holds at $2.96Wave Truncation - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma - Yahoo Finance
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5.3 - Moomoo
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move? - Sahm
RXRX|Recursion Pharmaceuticals Inc|Price:3.160|Chg%:-0.150 - TradingKey
Recursion Pharmaceuticals Stock Short Interest Rises to 35.35% - Moomoo
Jim Cramer: Utilities Stocks 'Oversold,' Fastly 'Back From Abyss'Cloudflare (NYSE:NET), Akamai Technol - Benzinga
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
$Recursion Pharmaceuticals (RXRX.US)$ panic selling by retail investors... [Awkward] - Moomoo
Recursion (RXRX) Q2 2026 Earnings Call Transcript - AOL.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Pipeline Catalysts - Moomoo
Recursion Pharmaceuticals (RXRX) Institutional Ownership 2026 $RXRX - marketbeat.com
Stock Traders Purchase High Volume of Put Options on Recursion Pharmaceuticals (NASDAQ:RXRX) - MarketBeat
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It's Not Tech) - 24/7 Wall St.
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Potential Upside of Over 120% Sparks Investor Interest - DirectorsTalk Interviews
Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships. - Pluang
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals (RXRX) Is Up 7.3% After Mixed Q2 Results With Narrower Net Loss - Sahm
What Does The Future Hold For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)? These Analysts Have Been Cutting Their Estimates - Moomoo
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analysts Just Trimmed Their Revenue Forecasts By 19% - simplywall.st
Recursion Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-08-09 - Seeking Alpha
Recursion Pharmaceuticals (NASDAQ:RXRX) Cut to "Strong Sell" at Wall Street Zen - marketbeat.com
Recursion Pharmaceuticals (RXRX) Reported Q2 Revenue Pressure, Is The Valuation Gap Too Wide? - simplywall.st
Recursion Pharmaceuticals director Blake Borgeson sells $97,500 in stock By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals Inc (RXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Recursion Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
Recursion Pharmaceuticals Inc (RXRX) Stock Analysis & Forecast - TradingKey
Recursion Pharmaceuticals (RXRX) Director Blake Borgeson Sells 3 - GuruFocus
Blake Borgeson Sells 30,000 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock - MarketBeat
Recursion Pharmaceuticals (RXRX) director sells 30,000 shares in 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals Insiders Sell US$790k Of Stock, Possibly Signalling Caution - Moomoo
Bank of New York Mellon Corp Boosts Stake in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals (RXRX) Stock Sinks As Cash Burn Dominates AI Drug Story - Sahm
Recursion Pharmaceuticals (RXRX) Stock Looks Weak On Returns While Trading Above Fair Value - simplywall.st
Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Recursion Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Recursion Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: Recursion misses Q2 2026 revenue forecast, shares fall premarket - Investing.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down Following Weak Earnings - MarketBeat
Recursion Pharmaceuticals Shares Fall After Q2 Miss - marketscreener.com
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):